Trial Profile
A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension [EXTENSION OF 700244310]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitaxentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 13 May 2014 New trial record
- 13 Dec 2010